S-farnesylcysteine alpha-carboxyl methyl ester: RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
S-farnesyl-L-cysteine : An S-polyprenyl-L-cysteine where the polyprenyl moiety is specified as farnesyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
S-[(2E,6E)-farnesyl]-L-cysteine methyl ester : An alpha-amino acid ester that is the methyl ester of S-[(2E,6E)-farnesyl]-L-cysteine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6439225 |
| CHEMBL ID | 1477730 |
| CHEBI ID | 87167 |
| CHEBI ID | 94600 |
| SCHEMBL ID | 14596316 |
| MeSH ID | M0183496 |
| Synonym |
|---|
| 125741-64-2 |
| farnesylcysteine methyl ester |
| s-fcme |
| l-cysteine, s-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, methyl ester |
| BRD-K38756014-001-02-8 |
| IDI1_033994 |
| BSPBIO_001524 |
| SPECTRUM5_001959 |
| NCGC00161312-01 |
| NCGC00161312-02 |
| NCGC00161312-03 |
| NCGC00161312-04 |
| s-farnesylcysteine alpha-carboxyl methyl ester |
| HMS1989M06 |
| BML2-C12 |
| s-farnesyl-l-cysteine me |
| HMS1791M06 |
| HMS1361M06 |
| methyl (2r)-2-amino-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylpropanoate |
| s-farnesyl-l-cysteine methyl ester |
| chebi:87167 , |
| CHEMBL1477730 |
| methyl s-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-l-cysteinate |
| s-[(2e,6e)-farnesyl]-l-cysteine methyl ester |
| SCHEMBL14596316 |
| HMS3402M06 |
| J-005281 |
| unii-p409g2h90a |
| l-cysteine, s-((2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)-, methyl ester |
| s-trans,trans-farnesyl-l-cysteine methyl ester |
| 130062-64-5 |
| l-cysteine, s-((2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienyl)-, methyl ester |
| P409G2H90A , |
| l-cysteine, s-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, methyl ester, (e,e)- |
| s-farnesyl cysteine methyl ester |
| CHEBI:94600 |
| s-farnesyl-l-cysteine |
| Q27159423 |
| 5U0 , |
| s fcme |
| sfcme |
| methyl s-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-l-cysteinate |
| AKOS040746342 |
| Class | Description |
|---|---|
| L-cysteine derivative | A proteinogenic amino acid derivative resulting from the formal reaction of L-cysteine at the amino group, carboxy group, or thiol group, or from the replacement of any hydrogen of L-cysteine by a heteroatom. |
| alpha-amino acid ester | The amino acid ester derivative obtained the formal condensation of an alpha-amino acid with an alcohol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Metabolism of proteins | 1058 | 144 |
| Post-translational protein modification | 666 | 112 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | 46 | 26 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 35.4813 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| TDP1 protein | Homo sapiens (human) | Potency | 18.4782 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 15.8489 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 0.0452 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||